阿奇霉素结构式
|
常用名 | 阿奇霉素 | 英文名 | Azithromycin |
---|---|---|---|---|
CAS号 | 83905-01-5 | 分子量 | 748.984 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 822.1±65.0 °C at 760 mmHg | |
分子式 | C38H72N2O12 | 熔点 | 113-115°C | |
MSDS | 中文版 美版 | 闪点 | 451.0±34.3 °C | |
符号 |
GHS08 |
信号词 | Danger |
阿奇霉素用途Azithromycin 是一种大环内酯抗生素,常用于治疗细菌感染。 |
中文名 | 阿奇霉素 |
---|---|
英文名 | azithromycin |
中文别名 | 阿齐霉素 | 阿奇霉素杂质 B |
英文别名 | 更多 |
描述 | Azithromycin 是一种大环内酯抗生素,常用于治疗细菌感染。 |
---|---|
相关类别 | |
体外研究 | 阿奇霉素(2μM)增强鼻病毒诱导的IFNβ在哮喘患者原发性支气管上皮细胞中的表达,这与RIG-I样受体的过度表达和病毒复制的抑制有关。敲除MDA5,但不抑制RIG-I,减少阿奇霉素(2μM)-增强哮喘原发性支气管上皮细胞中病毒诱导的IFNβ表达[1]。阿奇霉素特异性降低MMP-9 mRNA和蛋白水平,而不影响内毒素攻击的单核细胞THP-1细胞中的NF-κB[2]。 |
体内研究 | 在哮喘急性发作的小鼠模型中,阿奇霉素(50mg/kg)对支气管肺泡灌洗炎症参数和LDH水平没有影响。阿奇霉素在哮喘急性发作的小鼠模型中既不诱导一般的炎症参数也不诱导LDH释放,并且在加剧的小鼠中增强干扰素刺激的基因和模式识别受体MDA5而不是RIG-1的表达[1]。 |
细胞实验 | 将THP-1细胞(在1mL RPMI培养基中的106个细胞,不含抗生素,生长因子或血清)接种在24孔板的每个孔中并使其静置1小时。接下来,添加50μL测试化合物,接着添加50μLLPS(终浓度10μg/ mL)。 24小时(37℃和5%CO 2)后,收集上清液和细胞沉淀(1200rpm,5分钟)。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物(MTT)测试THP-1细胞活力。将MTT以2mg / mL溶解在PBS中,并将等分试样储存在-20℃。根据供应商的说明进行MTT测定。在570nm的波长下测量转化成甲的MTT的吸光度,在630nm处减去背景。 |
参考文献 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 822.1±65.0 °C at 760 mmHg |
熔点 | 113-115°C |
分子式 | C38H72N2O12 |
分子量 | 748.984 |
闪点 | 451.0±34.3 °C |
精确质量 | 748.508545 |
PSA | 180.08000 |
LogP | 3.33 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 0.0±0.6 mmHg at 25°C |
折射率 | 1.537 |
储存条件 | Store at -20°C |
稳定性 | Stable. Incompatible with strong oxidizing agents. |
计算化学 | 1、 疏水参数计算参考值(XlogP):4 2、 氢键供体数量:5 3、 氢键受体数量:14 4、 可旋转化学键数量:7 5、 互变异构体数量: 6、 拓扑分子极性表面积(TPSA):180 7、 重原子数量:52 8、 表面电荷:0 9、 复杂度:1150 10、同位素原子数量:0 11、确定原子立构中心数量:18 12、不确定原子立构中心数量:0 13、确定化学键立构中心数量:0 14、不确定化学键立构中心数量:0 15、共价键单元数量:1 |
更多 | 一、物性数据 1. 性状:白色结晶。 2. 密度(g/mL,25/4℃):不确定 3. 相对蒸汽密度(g/mL,空气=1):不确定 4. 熔点(ºC):113~115℃ 5. 沸点(ºC,0.67kpa或5 mmHg):不确定 6. 折射率:不确定 7. 闪点(ºC):不确定 8. 比旋光度(ºC):不确定 9. 自燃点或引燃温度(ºC)不确定 10. 蒸气压(kPa,25ºC):不确定 11. 饱和蒸气压(kPa,60ºC):不确定 12. 燃烧热(KJ/mol):不确定 13. 临界温度(ºC):50.3 14. 临界压力(KPa):不确定 15. 油水(辛醇/水)分配系数的对数值:不确定 16. 爆炸上限(%,V/V):不确定 17. 爆炸下限(%,V/V):不确定 18. 溶解性:不确定。 |
阿奇霉素毒理学数据: 1、急性毒性:人类经口TDLo:32 mg/kg/9D-I;人类经口TDLo:21 mg/kg/3D-I;大鼠经口LD50:>2mg/kg;大鼠腹膜腔LDLo:900mg/kg;小鼠经口LD50:3mg/kg;小鼠腹膜腔LDLo:400mg/kg; 2、其他多剂量毒性:大鼠经口TDLo:3600 mg/kg/36D-I;狗经口TDLo:3600 mg/kg/36D-I; 狗经口TDLo:6100 mg/kg/61D-I; 3、生殖毒性:受孕年5-21天的大鼠经口TDLo:1350 mg/kgSEX/DURATION; |
符号 |
GHS08 |
---|---|
信号词 | Danger |
危害声明 | H317-H334 |
警示性声明 | P261-P280-P342 + P311 |
个人防护装备 | Eyeshields;Faceshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
危害码 (欧洲) | Xi: Irritant; |
风险声明 (欧洲) | 42/43 |
安全声明 (欧洲) | 22-36/37-45 |
危险品运输编码 | NONH for all modes of transport |
RTECS号 | RN6960000 |
海关编码 | 2941500000 |
~88% 阿奇霉素 83905-01-5 |
文献:KOPRAN RESEARCH LABORATORIES LTD Patent: WO2007/15265 A2, 2007 ; Location in patent: Page/Page column 12-13 ; |
~89% 阿奇霉素 83905-01-5 |
文献:Kim, Hyoung Cheul; Kang, Sung Ho Angewandte Chemie - International Edition, 2009 , vol. 48, # 10 p. 1827 - 1829 |
~% 阿奇霉素 83905-01-5 |
文献:WO2007/80507 A2, ; Page/Page column 12 ; |
~% 阿奇霉素 83905-01-5 |
文献:Tetrahedron, , vol. 53, # 50 p. 16923 - 16944 |
以红霉素A为原料,经肟化后,在盐酸作用下进行Beckmann重排,再脱水、还原、甲基化可得阿奇霉素.
海关编码 | 2941500000 |
---|
Pseudomonas aeruginosa Biofilm Formation and Persistence, along with the Production of Quorum Sensing-Dependent Virulence Factors, Are Disrupted by a Triterpenoid Coumarate Ester Isolated from Dalbergia trichocarpa, a Tropical Legume.
PLoS ONE 10 , e0132791, (2015) Recently, extracts of Dalbergia trichocarpa bark have been shown to disrupt P. aeruginosa PAO1 quorum sensing (QS) mechanisms, which are key regulators of virulence factor expression and implicated in... |
|
Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum.
BMC Biol. 13 , 52, (2015) Malaria invasion of red blood cells involves multiple parasite-specific targets that are easily accessible to inhibitory compounds, making it an attractive target for antimalarial development. However... |
|
Purification and characterization of the Staphylococcus aureus bacillithiol transferase BstA.
Biochim. Biophys. Acta 1840(9) , 2851-61, (2014) Gram-positive bacteria in the phylum Firmicutes synthesize the low molecular weight thiol bacillithiol rather than glutathione or mycothiol. The bacillithiol transferase YfiT from Bacillus subtilis wa... |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside |
6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside |
N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-on |
Azithromycin |
Ribotrex |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2, |
2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside |
MFCD00873574 |
Tobil |
Zistic |
Azithral |
Arzomicin |
Zithromac |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl |
xz405 |
Aztrin |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one |
Setron |
1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b η-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(diméthylamino)-3-hydroxy-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-2-éthyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-méthoxy-4,6-diméthyltétrahydro-2H-pyran-2-yl]oxy}-3,5,6,8,10,12,14-heptaméthyl-1-oxa-6-azacyclopentadécan-15-one |
Aruzilina |
Zeto |
1-oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- |
Azadose |
Aziwok |
Azimin |
Azenil |
9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin A |
azithromycinum [INN_la] |
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside |
XZ-450 |
Zifin |
Ultreon |
1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- |